154 related articles for article (PubMed ID: 38619033)
1. A New Model Including AMH Cut-off Levels to Predict Post-treatment Ovarian Function in Early Breast Cancer: A Prospective Cohort Study.
Omranipour R; Ahmadi-Harchegani F; Saberi A; Moini A; Shiri M; Jalaeefar A; Arian A; Seifollahi A; Madani M; Eslami B; Alipour S
Arch Iran Med; 2024 Feb; 27(2):96-104. PubMed ID: 38619033
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
4. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
7. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys® AMH assay: a prospective observational study.
Grynnerup AG; Løssl K; Pilsgaard F; Lunding SA; Storgaard M; Bogstad JW; Prætorius L; Zedeler A; Bungum L; Nyboe Andersen A; Pinborg A
Reprod Biol Endocrinol; 2019 Jan; 17(1):11. PubMed ID: 30634990
[TBL] [Abstract][Full Text] [Related]
9. Assessment of ovarian reserve after hysterectomy: Laparoscopic vs. non-laparoscopic surgery.
Cho HY; Park ST; Kyung MS; Park SH
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():54-57. PubMed ID: 27940394
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mullerian Hormone Changes Following Laparoscopic Ovarian Cystectomy: A Prospective Comparative Study.
Cho HY; Park ST; Park SH; Kyung MS
Int J Womens Health; 2021; 13():691-698. PubMed ID: 34285593
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study.
Tzeng CR; Huang Z; Asada Y; Zhang C; Ho MT; Li RHW; Kim JH; Govindarajan M; Vuyavanich T; Sini I; Wong PS; Singh S; Lin WY; Ho NT
Hum Reprod; 2023 Jul; 38(7):1368-1378. PubMed ID: 37105234
[TBL] [Abstract][Full Text] [Related]
12. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
[TBL] [Abstract][Full Text] [Related]
13. Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
Mailliez A; Pigny P; Bogart E; Keller L; D'Orazio E; Vanseymortier M; Le Deley MC; Decanter C
Int J Cancer; 2022 Jun; 150(11):1850-1860. PubMed ID: 35038360
[TBL] [Abstract][Full Text] [Related]
14. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
15. A multicentre evaluation of the Elecsys
Jacobs MH; Reuter LM; Baker VL; Craig LB; Sakkas D; Surrey E; Doody KJ; Jungheim ES; Bayrak AB; Hund M; Verhagen-Kamerbeek WDJ; Pardue D; Buck K; Timm B
Reprod Biomed Online; 2019 May; 38(5):845-852. PubMed ID: 30930183
[TBL] [Abstract][Full Text] [Related]
16. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation.
Liebenthron J; Reinsberg J; van der Ven K; Saenger N; Kruessel JS; von Wolff M
Hum Reprod; 2019 Dec; 34(12):2513-2522. PubMed ID: 31782794
[TBL] [Abstract][Full Text] [Related]
18. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
19. Extended fertility at highly advanced reproductive age is not related to anti-Müllerian hormone concentrations.
Rotshenker-Olshinka K; Michaeli J; Srebnik N; Samueloff A; Magen S; Farkash R; Eldar-Geva T
Reprod Biomed Online; 2022 Jul; 45(1):147-152. PubMed ID: 35534396
[TBL] [Abstract][Full Text] [Related]
20. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
